<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36131932</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID.</ArticleTitle><Pagination><StartPage>939989</StartPage><MedlinePgn>939989</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">939989</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.939989</ELocationID><Abstract><AbstractText>The World Health Organization has defined long COVID-19 (LC) as a condition that occurs in individuals with a history of SARS-CoV-2 infection who exhibit persistent symptoms after its acute phase that last for at least two months and cannot be explained by an alternative diagnosis. Since we had previously reported residual viral antigens in tissues of convalescent patients, we aimed to assess the presence of such antigens in long COVID tissues.&#xa0;Here, we established the presence of the residual virus in the appendix, skin, and breast tissues of 2 patients who exhibited LC symptoms 163 and 426 days after symptom onset. With multiplex immunohistochemistry, we detected viral nucleocapsid protein in all three tissues. The nucleocapsid protein was further observed to colocalize with macrophage marker CD68, suggesting that immune cells were direct targets of SARS-CoV-2. Additionally, using RNAscope, the presence of viral RNA was also detected.&#xa0;Our positive finding in the breast tissue is corroborated by the recent reports of immunocompromised patients experiencing LC symptoms and persistent viral replication.&#xa0;Overall, our findings and emerging LC studies raise the possibility that the gastrointestinal tract may function as a reservoir for SARS-CoV-2.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Goh, Lim, Ferna&#xed;ndez, Joseph, Edwards, Neo, Lee, Caballero, Lau and Yeong.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goh</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Jeffrey Chun Tatt</ForeName><Initials>JCT</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferna&#xed;ndez</LastName><ForeName>Sonia Bilbao</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Long Covid Autonomous Comm unities Together Spain (Research Group), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Craig Ryan</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Sara Gil</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Vetcare Hospital Veterinario 24h, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neo</LastName><ForeName>Zhen Wei</ForeName><Initials>ZW</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Justina Nadia</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caballero</LastName><ForeName>S&#xed;lvia Guerrero</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Long Covid Autonomous Comm unities Together Spain (Research Group), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Mai Chan</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeong</LastName><ForeName>Joe Poh Sheng</ForeName><Initials>JPS</Initials><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Front Immunol. 2022 Oct 06;13:1036894. doi: 10.3389/fimmu.2022.1036894</RefSource><PMID Version="1">36275692</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">multiplex immunohistochemistry</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">residual SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">viral persistence</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>3</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36131932</ArticleId><ArticleId IdType="pmc">PMC9483160</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.939989</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. Condition WHOCCDWGoP-c-. a clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis (2021) 3099(21):00703&#x2013;9. S1473-. doi:&#xa0;10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurath MF, &#xdc;berla K, Ng SC. Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19. Gut (2021) 70(9):1605&#x2013;8. doi: 10.1136/gutjnl-2021-324622</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324622</ArticleId><ArticleId IdType="pubmed">33903146</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Gu S, Chen Y, Lu H, Shi D, Guo J, et al. . Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut (2022) 71:222&#x2013;5. doi: 10.1136/gutjnl-2021-324090</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324090</ArticleId><ArticleId IdType="pmc">PMC8666823</ArticleId><ArticleId IdType="pubmed">33833065</ArticleId></ArticleIdList></Reference><Reference><Citation>Trypsteen W, Van Cleemput J, Wv S, Gerlo S, Vandekerckhove L. On the whereabouts of SARS-CoV-2 in the human body: A systematic review. PLoS Pathogens (2020) 16(10):e1009037. doi: 10.1371/journal.ppat.1009037</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009037</ArticleId><ArticleId IdType="pmc">PMC7679000</ArticleId><ArticleId IdType="pubmed">33125439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM, Beumer J, Jvd V, Knoops K, Puschhof J, Breugem TI, et al. . SARS-CoV-2 productively infects human gut enterocytes. Science (2020) 369(6499):50&#x2013;4. doi: 10.1126/science.abc1669</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1669</ArticleId><ArticleId IdType="pmc">PMC7199907</ArticleId><ArticleId IdType="pubmed">32358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CCL, Goh D, Lim X, Tien TZ, Lim JCT, Lee JN, et al. . Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut (2022) 71(1):226&#x2013;9. doi: 10.1136/gutjnl-2021-324280</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324280</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Cardona A, Lloreta Trull J, Albero-Gonz&#xe1;lez R, Paraira Beser M, And&#xfa;jar X, Ruiz-Ramirez P, et al. . SARS-CoV-2 identified by transmission electron microscopy in lymphoproliferative and ischaemic intestinal lesions of COVID-19 patients with acute abdominal pain: two case reports. BMC Gastroenterol (2021) 21(1):334. doi: 10.1186/s12876-021-01905-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-021-01905-3</ArticleId><ArticleId IdType="pmc">PMC8390036</ArticleId><ArticleId IdType="pubmed">34445965</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. . Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut (2020) 69(6):1010. doi: 10.1136/gutjnl-2020-320953</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-320953</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, Pfister A, Meyer M, R&#xf6;ssler A, et al. . Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology (2022) 163(2):495&#x2013;506. doi:&#xa0;10.1053/j.gastro.2022.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Meringer H, Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. Nat Rev Gastroenterol Hepatol (2022) 19:345&#x2013;6. doi: 10.1038/s41575-022-00611-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-022-00611-z</ArticleId><ArticleId IdType="pmc">PMC8981882</ArticleId><ArticleId IdType="pubmed">35383321</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf F, Fahriani M, Mamada SS, Frediansyah A, Abubakar A, Maghfirah D, et al. . Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: A systematic review and meta-analysis. F1000Res (2021) 10:301&#x2013;. doi: 10.12688/f1000research.52216.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.52216.1</ArticleId><ArticleId IdType="pmc">PMC8171196</ArticleId><ArticleId IdType="pubmed">34131481</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes N, Dom&#xe8;nech &#xc8;, Guerrero S, Oliv&#xe1;n-Bl&#xe1;zquez B, Magall&#xf3;n-Botaya R. Analysis of cell-mediated immunity in people with long COVID. medRxiv (2021) 2021:06. doi: 10.1101/2021.06.09.21258553</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.09.21258553</ArticleId></ArticleIdList></Reference><Reference><Citation>Media statement from director Rochelle p. walensky, MD, MPH, on signing the advisory committee on immunization practices&#x2019; recommendation for an additional dose of an mRNA COVID-19 vaccine in moderately to severely immunocompromised people. (2021).</Citation></Reference><Reference><Citation>Nussenblatt V, Roder AE, Das S, de Wit E, Youn J-H, Banakis S, et al. . Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with b cell depletion. J Infect Dis (2021) jiab622. doi: 10.1101/2021.10.02.21264267</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.02.21264267</ArticleId><ArticleId IdType="pmc">PMC8755281</ArticleId><ArticleId IdType="pubmed">34940844</ArticleId></ArticleIdList></Reference><Reference><Citation>Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech A-M, Lane C, et al. . Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis (2020) 222(7):1103&#x2013;7. doi: 10.1093/infdis/jiaa446</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa446</ArticleId><ArticleId IdType="pmc">PMC7454684</ArticleId><ArticleId IdType="pubmed">32702095</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung WF, Chorlton S, Tyson J, Al-Rawahi GN, Jassem AN, Prystajecky N, et al. . COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report. Int J Infect Dis (2022) 114:178&#x2013;82. doi: 10.1016/j.ijid.2021.10.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.10.045</ArticleId><ArticleId IdType="pmc">PMC8553657</ArticleId><ArticleId IdType="pubmed">34757008</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim JCT, Yeong JPS, Lim CJ, Ong CCH, Wong SC, Chew VSP, et al. . An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use. Pathology (2018) 50(3):333&#x2013;41. doi: 10.1016/j.pathol.2017.11.087</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pathol.2017.11.087</ArticleId><ArticleId IdType="pubmed">29429740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, et al. . Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer (2020) 8(2):e000987. doi: 10.1136/jitc-2020-000987</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-000987</ArticleId><ArticleId IdType="pmc">PMC7451957</ArticleId><ArticleId IdType="pubmed">32847986</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeong J, Lim JCT, Lee B, Li H, Ong CCH, Thike AA, et al. . Prognostic value of CD8&#x2009;+&#x2009;PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. J ImmunoTher Cancer (2019) 7(1):34. doi:&#xa0;10.1186/s40425-019-0499-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-019-0499-y</ArticleId><ArticleId IdType="pmc">PMC6366051</ArticleId><ArticleId IdType="pubmed">30728081</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeong J, Lim JCT, Lee B, Li H, Chia N, Ong CCH, et al. . High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer. Front Immunol (2018) 9:1209&#x2013;. doi: 10.3389/fimmu.2018.01209</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01209</ArticleId><ArticleId IdType="pmc">PMC5988856</ArticleId><ArticleId IdType="pubmed">29899747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. . RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn (2012) 14(1):22&#x2013;9. doi: 10.1016/j.jmoldx.2011.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmoldx.2011.08.002</ArticleId><ArticleId IdType="pmc">PMC3338343</ArticleId><ArticleId IdType="pubmed">22166544</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al. . SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Sci (New York NY) (2020) 369(6505):812&#x2013;7. doi: 10.1126/science.abc4776</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc4776</ArticleId><ArticleId IdType="pmc">PMC7243369</ArticleId><ArticleId IdType="pubmed">32434946</ArticleId></ArticleIdList></Reference><Reference><Citation>Tostanoski LH, Wegmann F, Martinot AJ, Loos C, McMahan K, Mercado NB, et al. . Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat Med (2020) 26(11):1694&#x2013;700. doi: 10.1038/s41591-020-1070-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1070-6</ArticleId><ArticleId IdType="pmc">PMC7671939</ArticleId><ArticleId IdType="pubmed">32884153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>